7 research outputs found

    Motor neuron-derived Thsd7a is essential for zebrafish vascular development via the Notch-dll4 signaling pathway.

    Get PDF
    BackgroundDevelopment of neural and vascular systems displays astonishing similarities among vertebrates. This parallelism is under a precise control of complex guidance signals and neurovascular interactions. Previously, our group identified a highly conserved neural protein called thrombospondin type I domain containing 7A (THSD7A). Soluble THSD7A promoted and guided endothelial cell migration, tube formation and sprouting. In addition, we showed that thsd7a could be detected in the nervous system and was required for intersegmental vessels (ISV) patterning during zebrafish development. However, the exact origin of THSD7A and its effect on neurovascular interaction remains unclear.ResultsIn this study, we discovered that zebrafish thsd7a was expressed in the primary motor neurons. Knockdown of Thsd7a disrupted normal primary motor neuron formation and ISV sprouting in the Tg(kdr:EGFP/mnx1:TagRFP) double transgenic zebrafish. Interestingly, we found that Thsd7a morphants displayed distinct phenotypes that are very similar to the loss of Notch-delta like 4 (dll4) signaling. Transcript profiling further revealed that expression levels of notch1b and its downstream targets, vegfr2/3 and nrarpb, were down-regulated in the Thsd7a morphants. These data supported that zebrafish Thsd7a could regulate angiogenic sprouting via Notch-dll4 signaling during development.ConclusionsOur results suggested that motor neuron-derived Thsd7a plays a significant role in neurovascular interactions. Thsd7a could regulate ISV angiogenesis via Notch-dll4 signaling. Thus, Thsd7a is a potent angioneurin involved in the development of both neural and vascular systems

    Additional file 3: Figure S2. of Motor neuron-derived Thsd7a is essential for zebrafish vascular development via the Notch-dll4 signaling pathway

    No full text
    The approach of construct thsd7a transgenic zebrafish. Representative image is the flow chart of making transgenic fish construct. PCR amplified cassette containing GFP was flanked by target homologous BAC sequence indicated by gray box. The target homologous site was designed to locate between the thsd7a translational start site and the first exon. BAC containing PCR product and thsd7a promoter were then electroporated into EL250 competent cells which can induce homologous recombination activity. The end product was microinjected into zebrafish embryos at one-to-two cell stages. (PNG 156 kb

    Additional file 4: Figure S3. of Motor neuron-derived Thsd7a is essential for zebrafish vascular development via the Notch-dll4 signaling pathway

    No full text
    The tip cells on ISV showed protrusions without specific orientation in Thsd7a knockdown zebrafsih. Representative images showed the effects of Thsd7a knockdown by injecting Thsd7a MO2 into Tg(fli1:EGFP) zebrafish embryos; 5msMO2 was used as control. The morphants were then observed at 27 ~ 34hpf. In the control group, the tip cell on ISV displayed tree-shape morphology with single main protrusion (A and B). After knockdown of Thsd7a, the tip cell displayed fan-shape morphology with disorientation (C and D). Scale bar is 10 μm. (PNG 683 kb

    Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer

    No full text
    In our previous study, a series of novel cyclic cyanoguanidine compounds, eg. 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4- pyrimidinone derivatives have been successfully synthesized and showed remarkable cytotoxicity in several cancer cell lines. In this present study, it is our aim to screen more potential candidates among the cyclic pyridyl cyanoguanidine compounds (BPR-DC-1, 2, 3) by in vitro and in vivo studies for the therapy of lung cancer, alternatively. Our results showed that BPR-DC-2 significantly inhibited proliferation of tumor cells with an IC50 of 3.60 +/- 1.27 and 14.81 +/- 4.23 mu M in human lung carcinoma cells, H69 and A549, respectively by the MTT assay at 48 hr; BPR-DC-2 also obviously suppressed the tumor proliferation and MDR-1 gene expression, even induced cell apoptosis in the ex vivo histocultured lung tumor. We further demonstrated that, in the nude mouse model of metastatic lung cancer, BPR-DC-2 could diminish the tumor mass, retard the progression of metastasis, and prolong the survival time. In addition, it was found that BPR-DC-2 exerted its anti-tumor effects through the inhibition of MDR-1 gene expression and down-regulation of tumor anti-apoptosis signals (activated p-AKT and over-expression of PARP-1) by western blotting analysis. In conclusion, in this present study we have demonstrated that BPR-DC-2, derived from a series of novel synthetic cyclic cyanoguanidine compounds, has proved its potential as an anti-tumor drug candidate in treating lung cancer
    corecore